Endometrial Cancer Trial, Recruiting NCT05857631 Sponsor: Tata Memorial Centre Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT05857631
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have a performance status score of 0 to 2 on a standard scale used by doctors to measure how well a person is able to carry out daily activities (confirm with trial site)
  • People who have been confirmed by tissue testing to have cervical cancer after having a hysterectomy, where the cancer has certain intermediate or high-risk features that mean radiation treatment to the pelvis is needed, with or without chemotherapy
  • People who have been confirmed by tissue testing to have endometrial (uterine) cancer after having a hysterectomy, where radiation treatment to the pelvis is needed after surgery, with or without chemotherapy, and with or without internal radiation treatment to the vagina

Who may not be able to join:

  • People who had visible cancer remaining in the body after their surgery
  • People whose cancer has spread to lymph nodes near the large abdominal blood vessel (the aorta), requiring a wider area of radiation treatment than standard pelvic radiation
  • People who have previously received chemotherapy for any cancer at any point in their life
  • People who have previously had radiation treatment to the pelvic area
  • People who have HIV infection
  • People who have pre-existing health conditions that could affect the assessment of bowel or bladder side effects during the trial, such as irritable bowel syndrome, partial bowel blockage, bowel incontinence, hemorrhoids that would make bowel assessments difficult, urinary incontinence, or recurring urinary tract infections

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Dr. Prachi D Mittal, MD, Tata Memorial Hospital

Phone: +91 9004938871

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Tata Memorial Centre
Registry
ClinicalTrials.gov
Start date
29 May 2023
Est. completion
25 May 2029

Where this trial is recruiting

🇮🇳 India

Primary endpoints

3-year cumulative incidence of grade ≥2 gastrointestinal or genitourinary toxicity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov